Primary open-angle glaucoma
Conditions
Interventions
Trade Name: Timoptol 5,0 mg/ml (0,5%)
Product Name: Timoptol 5,0 mg/ml (0,5%)
Pharmaceutical Form: Eye drops, solution
INN or Proposed INN: Timolol
CAS Number: 26839-75-8
Other descriptive name: TIMOL
Sponsors
University Hospitals Leuven
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients over 18 years old Willing to give a written consent Patient with primary-open angle glaucoma Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20
Exclusion criteria
Exclusion criteria: history of ocular trauma intraocular surgery (except for cataract surgery) eye disease associated with hemodynamic disturbances (except glaucoma) systemic diseases with ocular involvement like diabetes contra-indications to the use of topical beta-blockers or carbonic anhydrase inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary aim of this study is to determine whether topical glaucoma medications can have an effect on the autoregulation ability by the ocular circulation, as assessed by color Doppler Imaging;Secondary Objective: Not applicable;Primary end point(s): The study aims at identify whether adding dorzolamide to pre-existing timolol therapy can change the resistivity/pulsatility ratio of the retrobulbar arteries in glaucomatous eyes. ;Timepoint(s) of evaluation of this end point: The timepoint for assessing the primary end point would take place at the second study visit (scheduled to take place 4 weeks after the first visit). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): A change in the overall Doppler waveform (systolic and diastolic mean velocities and early systolic acceleration) of the retrobulbar arteries will also be assessed. ;Timepoint(s) of evaluation of this end point: The timepoint for assessing the primary end point would take place at the second study visit (scheduled to take place 4 weeks after the first visit). | — |
Countries
Belgium
Contacts
Public ContactIngeborg Stalmans
University Hospitals Leuven
Outcome results
None listed